Other sunitinib treatment programs for MRCC may be worth the switch -
By Afsaneh Gray, medwireNews Reporter
Some patients with renal cell carcinoma metastatic (MRCC), which are moved from a traditional sunitinib treatment program at an hourly rate better alternative to survival measures and suffer fewer side effects, a Japanese study has found.
The transition from traditional to alternative schedules was recently shown to be effective. But "Japanese patients with mRCC significantly different experience [adverse events] than do patients in many other countries, probably because of genetic differences underlying" the authors write.
They retrospectively reviewed the medical records of 54 patients with MRCC who received treatment sunitinib as first-line treatment between May 06 and June 2012.
Thirty-two patients received traditional 4 weeks, 2 weeks off (4/2) the processing schedule, while 22 received an alternative program. The group of alternative schedule included 17 patients s who started the therapy on the 4/2 schedule but changed due to adverse events shortly after the start of treatment.
At the time of administration of sunitinib, five patients were considered to have a favorable prognosis, according to the assessment of the risk classification Memorial Sloan Kettering Cancer Center, while 42 had intermediate and seven predictions had a poor prognosis.
average observation periods differ between traditional and alternative planning groups, with those on another calendar with an average of 20 months of follow-up compared to 16.3 months.
survival measures were significantly improved in patients on replacement schedules, compared to those on traditional schedules, and adverse events were significantly less common, including many effects more serious treatment.
The median time to treatment failure was 11.6 months on the replacement schedule compared to 4.1 months on the traditional calendar, while the median PFS was 11, three months against 4.1 months and the median overall survival was 32.1 months against 12.0 months.
"Each of these measures was better in the group of patients who received an alternative treatment schedule, suggesting that the individual changes to the schedule of administration of sunitinib may be effective," study researcher Takeshi Ueda (Chiba Cancer Center) and colleagues write in the International Journal of Urology .
They note that sunitinib has been shown previously to provide robust therapeutic effects in patients were first experience adverse events, which may partly explain the better survival in the alternative planning group.
"We believe that the transition to [alternative schedule] reduces [adverse events] and periods prolonged treatment, which could provide additional benefits, "the researchers explain
But they warn :.". these results should be interpreted with caution, and larger prospective studies are needed to other institutions to validate these results "
licensed medwireNews with Springer Healthcare Ltd. permission © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.
EmoticonEmoticon